Drugs / Gamma-Interferon-1b
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00786643 | Feb 2006 → Mar 2010 | colorectal cancer | Accelerated Community Oncology Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00028275 | Dec 2001 → Nov 2003 | chronic hepatitis C virus infection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gamma interferon 1b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00028275 ↗ |
| Known as | IFN-γ | “Gamma-Interferon-1b (IFN-γ)” NCT00786643 ↗ |
| Route | Subcutaneous | “patients will be randomized to receive either 100 or 200 mcg of gamma interferon 1b (provided by InterMune Pharmaceuticals, Inc) subcutaneously three times weekly for 4 weeks.” NCT00028275 ↗ |